Abstract

 CADTH recommends that Saxenda should not be reimbursed by public drug plans for chronic weight management in adult patients.
 Evidence from 3 studies demonstrated that Saxenda was associated with statistically significant reductions in body weight compared with placebo after 56 weeks of treatment.
 No conclusions could be drawn about long-term benefits, particularly for clinically meaningful improvements in comorbidities identified as priorities by patients, such as diabetes, sleep apnea, osteoarthritis, and cardiovascular complications.
 Patients identified a need for treatments that can improve potential obesity-related comorbidities, such as diabetes, sleep apnea, osteoarthritis, and cardiovascular complications. It is not clear whether Saxenda meets these needs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
